Just caught up on what Esperion is doing with this Corstasis acquisition, and honestly it's a pretty smart move for their cardiovascular play. ESPR announced they're picking up the company for $75M upfront, with another $180M possible if certain milestones hit. The main asset here is Enbumyst, which is basically the only nasal spray diuretic the FDA has approved for treating fluid buildup in heart failure and liver/kidney disease patients.

What's interesting about this deal is how it fills a gap. Right now you've got oral diuretics and then IV options, but nothing really in between for outpatient use. Enbumyst changes that. For ESPR, this makes sense strategically because they've already got Nexletol and Nexlizet doing solid work in their cardiovascular portfolio. Those two drugs grew net sales 38% in the first nine months of 2025, hitting $115.8M. So they're clearly gaining traction in this space.

The company is positioning this around a potential $4 billion market opportunity in the US alone. They're funding it through existing credit facilities and by monetizing Japanese royalties with help from Athyrium Capital and HealthCare Royalty. The deal should close sometime this quarter, which is coming up fast.

Now here's the thing - ESPR shares actually dropped 11% when this announcement hit, which is the kind of market reaction you sometimes see even with good strategic moves. Year to date the stock is down about 21%, underperforming the industry by a decent margin. Whether this acquisition changes that narrative remains to be seen, but on paper it looks like they're building out their cardiovascular franchise in a meaningful way. The addition of a differentiated diuretic option alongside their existing cholesterol and cardiovascular risk reduction drugs could be the catalyst that accelerates growth they're targeting.